Lung Cancer Clinical Trial
Official title:
African American Families and Lung Cancer Study
| Verified date | August 2, 2011 |
| Source | National Institutes of Health Clinical Center (CC) |
| Contact | n/a |
| Is FDA regulated | No |
| Health authority | |
| Study type | Observational |
This study will learn more about the beliefs of family members of African American patients
with lung cancer and whether these beliefs are associated with their interest in genetic
testing for disease risk and willingness to participate in genetics research. Lung cancer is
the second most common form of cancer and the leading cause of cancer deaths for men and
women in the United States. Like most cancers, there are racial and ethnic disparities (gaps)
in lung cancer cases and deaths. The age-adjusted rates for blacks and whites (years 2000 to
2003) was 76.9 per 100,000 and 66.0 per 100,000, respectively. Mortality rates were 62.5 per
100,000 for blacks and 55.3 per 100,000 for whites. Cigarette smoking is the most preventable
cause of lung cancer. Findings are that African Americans begin smoking at older ages and
smoke fewer cigarettes per day than Caucasian Americans do. Yet the severity of lung cancer
is greater for African Americans. Behavioral, social, environmental, and genetic factors may
explain the differences.
Participants (subjects) ages 18 to 55 who are family of patients with lung cancer who
self-identify as African Americans may be eligible for this study. Washington, D.C.,
researchers plan to recruit 115 lung cancer patients and 200 family members-100 current
smokers and 100 who never smoked. Lung cancer patients, who must have been born in the United
States, will be recruited from those who are receiving care at the Washington Cancer
Institute at the Washington Hospital Center. They will be asked to list relatives and friends
they consider to be as close as family. Patients will be asked permission for researchers to
contact those people. Family members will receive a letter telling them that unless they
decline to participate, they will be contacted by a telephone interviewer.
The survey will feature questions to evaluate family members' explanations for the causes of
lung cancer, as well as their reactions to possible reasons for the disparity in lung cancer
between African Americans and Caucasian Americans. Subjects will be asked about perceived
personal risk, worry about developing lung cancer, smoking history, motivation to quit
smoking, feelings about the lung cancer patient's diagnosis, racial identify, experience with
racial discrimination, pros and cons of genetic testing, and interest in genetic testing. The
survey will take up to 20 minutes to complete.
This study may or may not have a direct benefit for those who participate. However, lung
cancer patients and their families will be offered a free self-help guide to stop smoking.
They will be referred to local smoking cessation programs. Knowledge gained from the study
may be used to design smoking cessation methods and research studies related to genetics for
minority populations.
| Status | Completed |
| Enrollment | 400 |
| Est. completion date | August 2, 2011 |
| Est. primary completion date | |
| Accepts healthy volunteers | No |
| Gender | All |
| Age group | 18 Years and older |
| Eligibility |
- INCLUSION CRITERIA: Patients: In order to be included in this study, patients with lung cancer must meet inclusion criteria at 2 steps: (1) initial screening and written consent to be contacted by telephone, and (2) provision of verbal consent at the time of telephone contact to complete the survey. Step 1a: In order to be approached about the study, patients must be (1) at least 18 years of age, (2) diagnosed with lung cancer at any stage (Stages Ia-IV), (3) approved for contact by their oncologist, and (4) identified by the recruiter or identified in medical records as Black. Step 1b: In order to provide consent for contact for the telephone survey, patients must self-identify as AA/Black and must have been born in the U.S. Also, patients must be willing to give permission to contact at least one family member or friend considered as close as family who is a current cigarette smoker between the ages of 18 and 55 in order to provide consent. Step 2: At the point of the patient survey, all patients will be asked their race/ethnicity. All patients who self-identify as AA/Black as defined by this research will be administered the patient survey. Family: Family members must self-identify as AA and be between the ages of 18 and 55 to be eligible for the study. Family also must meet the following inclusion criteria to be classified as either a current smoker (defined below) or a never smoker (defined below). These criteria for current smoker and never smoker are based on standard criteria used in smoking research. Current Smoker: to be included as a smoker , the family member must report having smoked at least 100 cigarettes in their lifetime, and smoked 7 or more cigarettes in the past 7 days at the time of the family member survey. Never Smokers: to be included as a never smoker , a family member must report no to having smoked at least 100 cigarettes in their lifetime. EXCLUSION CRITERIA: Former smokers (i.e., family who have smoked at least 100 cigarettes in their lifetime but smoked fewer than 7 cigarettes in the past 7 days) because previous research shows consistently that these individuals hold attitudes and beliefs more similar to those of current smokers than never smokers. Patients who describe themselves as AA or Black but were not born in the U.S. will be excluded from participation. |
| Country | Name | City | State |
|---|---|---|---|
| United States | Washington Hospital Center | Washington, D.C. | District of Columbia |
| Lead Sponsor | Collaborator |
|---|---|
| National Human Genome Research Institute (NHGRI) |
United States,
Arthur CM, Katkin ES. Making a case for the examination of ethnicity of Blacks in United States Health Research. J Health Care Poor Underserved. 2006 Feb;17(1):25-36. — View Citation
Baty BJ, Kinney AY, Ellis SM. Developing culturally sensitive cancer genetics communication aids for African Americans. Am J Med Genet A. 2003 Apr 15;118A(2):146-55. — View Citation
Clark R, Anderson NB, Clark VR, Williams DR. Racism as a stressor for African Americans. A biopsychosocial model. Am Psychol. 1999 Oct;54(10):805-16. — View Citation
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT03918538 -
A Series of Study in Testing Efficacy of Pulmonary Rehabilitation Interventions in Lung Cancer Survivors
|
N/A | |
| Recruiting |
NCT05078918 -
Comprehensive Care Program for Their Return to Normal Life Among Lung Cancer Survivors
|
N/A | |
| Active, not recruiting |
NCT04548830 -
Safety of Lung Cryobiopsy in People With Cancer
|
Phase 2 | |
| Completed |
NCT04633850 -
Implementation of Adjuvants in Intercostal Nerve Blockades for Thoracoscopic Surgery in Pulmonary Cancer Patients
|
||
| Recruiting |
NCT06006390 -
CEA Targeting Chimeric Antigen Receptor T Lymphocytes (CAR-T) in the Treatment of CEA Positive Advanced Solid Tumors
|
Phase 1/Phase 2 | |
| Recruiting |
NCT06037954 -
A Study of Mental Health Care in People With Cancer
|
N/A | |
| Recruiting |
NCT05583916 -
Same Day Discharge for Video-Assisted Thoracoscopic Surgery (VATS) Lung Surgery
|
N/A | |
| Completed |
NCT00341939 -
Retrospective Analysis of a Drug-Metabolizing Genotype in Cancer Patients and Correlation With Pharmacokinetic and Pharmacodynamics Data
|
||
| Not yet recruiting |
NCT06376253 -
A Phase I Study of [177Lu]Lu-EVS459 in Patients With Ovarian and Lung Cancers
|
Phase 1 | |
| Recruiting |
NCT05898594 -
Lung Cancer Screening in High-risk Black Women
|
N/A | |
| Active, not recruiting |
NCT05060432 -
Study of EOS-448 With Standard of Care and/or Investigational Therapies in Participants With Advanced Solid Tumors
|
Phase 1/Phase 2 | |
| Active, not recruiting |
NCT03575793 -
A Phase I/II Study of Nivolumab, Ipilimumab and Plinabulin in Patients With Recurrent Small Cell Lung Cancer
|
Phase 1/Phase 2 | |
| Active, not recruiting |
NCT03667716 -
COM701 (an Inhibitor of PVRIG) in Subjects With Advanced Solid Tumors.
|
Phase 1 | |
| Terminated |
NCT01624090 -
Mithramycin for Lung, Esophagus, and Other Chest Cancers
|
Phase 2 | |
| Terminated |
NCT03275688 -
NanoSpectrometer Biomarker Discovery and Confirmation Study
|
||
| Not yet recruiting |
NCT04931420 -
Study Comparing Standard of Care Chemotherapy With/ Without Sequential Cytoreductive Surgery for Patients With Metastatic Foregut Cancer and Undetectable Circulating Tumor-Deoxyribose Nucleic Acid Levels
|
Phase 2 | |
| Recruiting |
NCT06052449 -
Assessing Social Determinants of Health to Increase Cancer Screening
|
N/A | |
| Recruiting |
NCT06010862 -
Clinical Study of CEA-targeted CAR-T Therapy for CEA-positive Advanced/Metastatic Malignant Solid Tumors
|
Phase 1 | |
| Not yet recruiting |
NCT06017271 -
Predictive Value of Epicardial Adipose Tissue for Pulmonary Embolism and Death in Patients With Lung Cancer
|
||
| Recruiting |
NCT05787522 -
Efficacy and Safety of AI-assisted Radiotherapy Contouring Software for Thoracic Organs at Risk
|